Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Consolidated Net Income: 2011-2024

Historic Consolidated Net Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $673.7 million.

  • Agios Pharmaceuticals' Consolidated Net Income fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Consolidated Net Income is $673.7 million, which was up 291.35% from -$352.1 million recorded in FY2023.
  • Agios Pharmaceuticals' 5-year Consolidated Net Income high stood at $2.0 billion for FY2021, and its period low was -$352.1 million during FY2023.
  • Over the past 3 years, Agios Pharmaceuticals' median Consolidated Net Income value was -$231.8 million (recorded in 2022), while the average stood at $29.9 million.
  • In the last 5 years, Agios Pharmaceuticals' Consolidated Net Income soared by 101,255.30% in 2021 and then tumbled by 111.82% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Consolidated Net Income (Yearly) stood at $1.9 million in 2020, then spiked by 101,255.30% to $2.0 billion in 2021, then crashed by 111.82% to -$231.8 million in 2022, then crashed by 51.89% to -$352.1 million in 2023, then skyrocketed by 291.35% to $673.7 million in 2024.